Altimmune, Inc.

Equities

ALT

US02155H2004

Real-time Estimate Cboe BZX Other stock markets 13:17:25 2025-06-18 EDT			5-day change	1st Jan Change
6.995 ^USD	+1.52%		+6.19%	-3.68%

05-23	Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025
05-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	RE

Altimmune, Inc., Q2 2024 Earnings Call, Aug 08, 2024

Published on 2024-08-08 at 08:30

Presentation Operator Message
Operator (Operator)

Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Altimmune, Inc.

Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025	05-23
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	05-19	RE
Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	05-19	CI
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital	05-13	MT
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital	05-13	RE
Altimmune Q1 Net Income USD -19.575 Million	05-13	RE
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Altimmune, Inc. Secures Up to $100 Million in Credit Facility from Hercules Capital	05-13	CI
Altimmune, Inc. announced that it expects to receive $100 million in funding	05-12	CI
Pfizer ends development of weight-loss pill danuglipron	04-14	RE
OPKO and Entera partner to develop obesity pill	03-17	RE
Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025	03-13	RE
Altimmune to test obesity drug for alcohol use disorder and related health conditions	03-13	RE
Altimmune, Inc. Pursues Two Additional Indications for Its Lead Product Candidate, Pemvidutide	03-13	CI
Altimmune, Inc. - Special Call	03-13
William Blair Initiates Altimmune at Market Perform	02-28	MT
Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing	02-27	RE
Altimmune, Inc., Q4 2024 Earnings Call, Feb 27, 2025	02-27
Altimmune, Inc. Announces Retirement of Scott Harris as Chief Medical Officer, Effective February 28, 2026	02-27	CI
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-27	CI
Altimmune, Inc. Announces Board Appointments	02-25	CI
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	10:42am	RE
Fat, not muscle: drugmakers in race for next weight-loss breakthrough	02-19	RE
Stifel Initiates Altimmune at Buy With $18 Price Target	01-08	MT